$19.49
Faringosept is a topical drug used as an auxiliary medication for the treatment of respiratory diseases of the oral cavity (tonsillitis, gingivitis and pharyngitis). The composition of Faringosept: ambazone, cocoa, sweetener, lactose, magnesium stearate, vanillin.
Ambazon is a local antiseptic with high activity against pathogenic microorganisms that most often cause infections of the oral cavity and upper respiratory tract: streptococci, pneumococci, and also has moderate antistaphylococcal activity. It does not affect the intestinal microflora, and therefore does not cause dysbiosis of the digestive tract.
In addition, the use of pressed lollipops causes increased salivation and the release of the body’s natural bactericidal substances (such as lysozyme) and at the same time moisturizes the mucous membrane and reduces irritation.
Symptomatic treatment of infections of the oral and nasopharyngeal mucosa: gingivitis, stomatitis, tonsillitis, angina, pharyngitis. Prevention of infectious complications after tonsillectomy and tooth extraction.
The recommended dose of the drug for adults and children over 7 years of age is 3-5 lozenges (30-50 mg of ambazone) per day for at least 3-4 days. Do not swallow the lozenges – they should be slowly dissolved with saliva in the oral cavity. The drug is used 15-30 minutes after a meal, after which you should not eat or drink for 2-3 hours.
The recommended dose for children aged 3-7 years is 1 lollipop 3 times a day (30 mg of ambazone) for 3-4 days.
Increasing the recommended dose does not increase the severity of the therapeutic effect.
Hypersensitivity to any component of the drug.
Hypersensitivity reactions are possible, including angioedema, urticaria, itching, facial flushing, and rash.
Since Faringosept lozenges contain sucrose and lactose, patients with rare hereditary forms of fructose or galactose intolerance, glucose-galactose malabsorption syndrome, or sucrase-isomaltase insufficiency or the Lapp lactase deficiency should avoid using the drug. Patients with diabetes mellitus should take into account that the lozenges contain sucrose.
Use during pregnancy and breastfeeding. There are no controlled clinical studies on the use of ambazone during pregnancy and breastfeeding. However, there are no data on adverse reactions or harm to the fetus when using ambazone during pregnancy. It is not known whether ambazone passes into breast milk.
Faringosept lozenges can be prescribed during pregnancy or breastfeeding only if, in the opinion of the doctor, the benefit to the mother outweighs the potential risk to the fetus.
Children: Do not use in children under 3 years of age.
Ability to influence the reaction rate when driving vehicles or working with other mechanisms. The drug does not affect the ability to drive vehicles or work with complex mechanisms.
To date, no interactions of the drug with other medications have been reported.
To date, no cases of overdose have been recorded. There is no specific antidote. When using a large number of Faringosept lozenges, induce vomiting and/or rinse the stomach.
In the original packaging at a temperature not exceeding 25 °C.
Reviews
There are no reviews yet.